Latest Insider Transactions at Fate Therapeutics Inc (FATE)
This section provides a real-time view of insider transactions for Fate Therapeutics Inc (FATE). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of FATE THERAPEUTICS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of FATE THERAPEUTICS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 06
2024
|
Yuan Xu |
SELL
Open market or private sale
|
Direct |
633
-6.81%
|
$2,532
$4.23 P/Share
|
|
Jul 29
2024
|
Bahram Valamehr Chief R&D Officer |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+35.84%
|
-
|
|
Jul 29
2024
|
Cindy Tahl General Counsel and Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+36.88%
|
-
|
|
Mar 04
2024
|
Edward J Dulac Iii Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,447
-2.35%
|
$17,129
$7.77 P/Share
|
|
Jan 29
2024
|
Edward J Dulac Iii Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,849
-1.75%
|
$9,245
$5.0 P/Share
|
|
Jan 09
2024
|
Edward J Dulac Iii Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
7,028
-6.23%
|
$28,112
$4.37 P/Share
|
|
Jan 09
2024
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
14,391
-3.73%
|
$57,564
$4.37 P/Share
|
|
Jan 09
2024
|
Bahram Valamehr Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
11,271
-6.66%
|
$45,084
$4.38 P/Share
|
|
Jan 09
2024
|
Cindy Tahl General Counsel and Secretary |
SELL
Open market or private sale
|
Direct |
10,874
-7.1%
|
$43,496
$4.37 P/Share
|
|
Jan 02
2024
|
Edward J Dulac Iii Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,182
-4.39%
|
$15,546
$3.66 P/Share
|
|
Dec 26
2023
|
Redmile Group, LLC Director |
BUY
Open market or private purchase
|
Indirect |
44,630
+0.34%
|
$133,890
$3.72 P/Share
|
|
Dec 26
2023
|
Redmile Group, LLC Director |
BUY
Other acquisition or disposition
|
Indirect |
1,655,370
+11.19%
|
$4,966,110
$3.72 P/Share
|
|
Dec 26
2023
|
Redmile Group, LLC Director |
SELL
Other acquisition or disposition
|
Indirect |
1,655,370
-11.19%
|
$4,966,110
$3.72 P/Share
|
|
Dec 18
2023
|
Edward J Dulac Iii Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,585
-1.33%
|
$4,755
$3.5 P/Share
|
|
Nov 09
2023
|
Cindy Tahl General Counsel and Secretary |
SELL
Open market or private sale
|
Direct |
24,363
-13.72%
|
$48,726
$2.4 P/Share
|
|
Aug 18
2023
|
Edward J Dulac Iii Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,718
-3.8%
|
$9,436
$2.8 P/Share
|
|
Aug 04
2023
|
Yuan Xu |
SELL
Open market or private sale
|
Direct |
632
-6.36%
|
$1,896
$3.71 P/Share
|
|
Jul 05
2023
|
Edward J Dulac Iii Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,182
-4.0%
|
$20,728
$4.83 P/Share
|
|
Jul 05
2023
|
Brian T. Powl Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,854
-8.56%
|
$15,416
$4.87 P/Share
|
|
Jun 14
2023
|
Yuan Xu |
SELL
Open market or private sale
|
Direct |
3,460
-25.83%
|
$17,300
$5.58 P/Share
|
|
Apr 21
2023
|
Redmile Group, LLC Director |
BUY
Open market or private purchase
|
Indirect |
256,639
+1.92%
|
$1,539,834
$6.18 P/Share
|
|
Apr 20
2023
|
Redmile Group, LLC Director |
BUY
Open market or private purchase
|
Indirect |
20,000
+0.16%
|
$100,000
$5.99 P/Share
|
|
Apr 18
2023
|
Yu Waye Chu Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,532
-0.89%
|
$15,192
$6.55 P/Share
|
|
Apr 14
2023
|
Redmile Group, LLC Director |
BUY
Open market or private purchase
|
Indirect |
25,700
+0.2%
|
$154,200
$6.0 P/Share
|
|
Apr 14
2023
|
Redmile Group, LLC Director |
BUY
Other acquisition or disposition
|
Indirect |
5,492,385
+29.97%
|
$27,461,925
$5.84 P/Share
|
|
Apr 14
2023
|
Redmile Group, LLC Director |
SELL
Other acquisition or disposition
|
Indirect |
5,492,385
-29.97%
|
$27,461,925
$5.84 P/Share
|
|
Apr 14
2023
|
Redmile Group, LLC Director |
SELL
Open market or private sale
|
Indirect |
302,339
-2.3%
|
$1,511,695
$5.84 P/Share
|
|
Apr 13
2023
|
Redmile Group, LLC Director |
BUY
Conversion of derivative security
|
Indirect |
167,205
+1.26%
|
-
|
|
Jan 19
2023
|
John Mendlein |
BUY
Exercise of conversion of derivative security
|
Direct |
28,461
+8.38%
|
$28,461
$1.37 P/Share
|
|
Jan 13
2023
|
John Mendlein |
BUY
Open market or private purchase
|
Direct |
36,631
+11.47%
|
$183,155
$5.43 P/Share
|
|
Jan 12
2023
|
Bahram Valamehr Chief R&D Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
423
+0.25%
|
$423
$1.37 P/Share
|
|
Jan 11
2023
|
John Mendlein |
BUY
Open market or private purchase
|
Direct |
88,048
+26.35%
|
$440,240
$5.67 P/Share
|
|
Jan 10
2023
|
Bahram Valamehr Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
10,917
-6.07%
|
$54,585
$5.24 P/Share
|
|
Jan 10
2023
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
45,907
-10.64%
|
$229,535
$5.24 P/Share
|
|
Jan 10
2023
|
Yu Waye Chu Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,825
-5.18%
|
$39,125
$5.24 P/Share
|
|
Jan 10
2023
|
Edward J Dulac Iii Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
7,331
-5.36%
|
$36,655
$5.24 P/Share
|
|
Jan 10
2023
|
Mark Plavsic Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
3,418
-2.69%
|
$17,090
$5.24 P/Share
|
|
Jan 10
2023
|
Cindy Tahl General Counsel and Secretary |
SELL
Open market or private sale
|
Direct |
11,553
-6.11%
|
$57,765
$5.24 P/Share
|
|
Aug 18
2022
|
Edward J Dulac Iii Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,135
-1.81%
|
$154,050
$30.08 P/Share
|
|
Jul 22
2022
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
6,246
-0.48%
|
$199,872
$32.41 P/Share
|
|
Jul 22
2022
|
J Scott Wolchko President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,246
+1.41%
|
$12,492
$2.7 P/Share
|
|
Jul 21
2022
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-3.3%
|
$960,000
$32.81 P/Share
|
|
Jul 21
2022
|
J Scott Wolchko President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+6.1%
|
$60,000
$2.7 P/Share
|
|
Jul 07
2022
|
Bahram Valamehr Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
17,158
-8.71%
|
$514,740
$30.23 P/Share
|
|
Jul 07
2022
|
Bahram Valamehr Chief R&D Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,158
+8.01%
|
$34,316
$2.73 P/Share
|
|
Jul 06
2022
|
Bahram Valamehr Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
7,842
-4.18%
|
$235,260
$30.07 P/Share
|
|
Jul 06
2022
|
Bahram Valamehr Chief R&D Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,842
+2.05%
|
$23,526
$3.79 P/Share
|
|
Jul 05
2022
|
Mark Plavsic Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
3,719
-2.84%
|
$89,256
$24.61 P/Share
|
|
Jun 27
2022
|
Brian T. Powl Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+50.0%
|
-
|
|
Jun 09
2022
|
Shefali Agarwal |
BUY
Grant, award, or other acquisition
|
Direct |
8,650
+45.19%
|
-
|